Article
CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.
The pharmacogenomics journal - 1 Apr 2018
de Denus S, Rouleau J L, Mann D L, Huggins G S, Pereira N L, Shah S H, Cappola T P, Fouodjio R, Mongrain I, Dubé M-P
Abstract excerpt
Despite its established inter-individual variability, sildenafil has been the subject of only a few pharmacogenetic investigations, with limited data regarding the genetic modulators of its pharmacokinetics. We conducted a pharmacogenetic sub-study of patients randomized to sildenafil (n=85) in the RELAX trial, which investigated the impact of high-dose sildenafil in patients with heart failure with preserved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.